Lovisa Berggren

512 citations

27 papers · 392 indexed · h-index 13

Co-authors: Catherine Datto Hans Eriksson O Hansson Martín Dossenbach Jitendra Patel Yves Dutronc Chris Bushe L. Puig
Topics: Treatment of Major Depression (8 papers)Attention Deficit Hyperactivity Disorder (7 papers)Psoriasis: Treatment and Pathogenesis (6 papers)
Cited by: Psychiatry and Mental health Biological Psychiatry Dermatology
Journals: The Lancet Journal of Investigative Dermatology Psychiatry Research
Partner nations: United States Germany United Kingdom

In The Last Decade

Lovisa Berggren

27 papers receiving 378 citations

Peers

Countries citing papers authored by Lovisa Berggren

Since Specialization

Citations

This map shows the geographic impact of Lovisa Berggren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lovisa Berggren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lovisa Berggren more than expected).

Fields of papers citing papers by Lovisa Berggren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lovisa Berggren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lovisa Berggren. The network helps show where Lovisa Berggren may publish in the future.

Co-authorship network of co-authors of Lovisa Berggren

This figure shows the co-authorship network connecting the top 25 collaborators of Lovisa Berggren. A scholar is included among the top collaborators of Lovisa Berggren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lovisa Berggren. Lovisa Berggren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis 2020 ·Acta Dermato Venereologica ·L. Puig,Mark Lomaga,Kristin Hollister,Yves Dutronc,Lovisa Berggren,P.C.M. van de Kerkhof	9
2	Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S) 2020 ·Dermatology and Therapy ·Norman Wasel,Diamant Thaçi,Lars E. French,Curdin Conrad,Yves Dutronc,Gaia Gallo,Lovisa Berggren,J.‐P. Lacour	24
3	Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes 2019 ·Acta Dermato Venereologica ·L. Puig,Martín Dossenbach,Lovisa Berggren,Anders Ljungberg,Claus Zachariae	27
4	Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies 2018 ·Dermatology and Therapy ·Gil Yosipovitch,Adam Reich,Martin Steinhoff,(unknown),Toby Kent,Martín Dossenbach,Lovisa Berggren,Carsten Henneges,Thomas A. Luger	13
5	Follow-up study of patients treated with olanzapine pamoate in France in real-life treatment situation 2017 ·L Encéphale ·(unknown),F. Rouillon,Lovisa Berggren,(unknown),Bruno Falissard,Pierre‐Michel Llorca	2
6	337 Long-term clinical outcomes after 2 years of Ixekizumab treatment in patients with moderate-to-severe psoriasis with a focus on absolute PASI 2017 ·Journal of Investigative Dermatology ·Pablo Fernández‐Peñas,Orin M. Goldblum,Lovisa Berggren,Nicole Y. Burkhardt,D. Jullien	5
7	Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being 2016 ·Neuropsychiatric Disease and Treatment ·Ernie Anand,Lovisa Berggren,John Landry,(unknown),Holland C. Detke	3
8	Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database 2016 ·CNS Drugs ·Chris Bushe,Esther Sobanski,David Coghill,Lovisa Berggren,(unknown),Sami Leppämäki	9
9	Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database 2016 ·CNS Drugs ·(unknown),Chris Bushe,(unknown),Lovisa Berggren,Cornelis C. Kan,Regina Dittmann	11
10	A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation 2015 ·Neuropsychiatric Disease and Treatment ·Ernie Anand,Lovisa Berggren,(unknown),(unknown),David McDonnell	9
11	Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors 2015 ·Human Psychopharmacology Clinical and Experimental ·David V. Sheehan,Michele Mancini,Jianing Wang,Lovisa Berggren,(unknown),Héctor Dueñas,Yue Li	22
12	The effects of atomoxetine on emotional control in adults with ADHD: An integrated analysis of multicenter studies 2015 ·European Psychiatry ·Philip Asherson,Steven Stes,(unknown),Lovisa Berggren,Pär Svanborg,Alexandra Kutzelnigg,Walter Deberdt	17
13	Patterns of long-term and short-term responses in adult patients with attention-deficit/hyperactivity disorder in a completer cohort of 12 weeks or more with atomoxetine 2015 ·European Psychiatry ·Esther Sobanski,Sami Leppämäki,Chris Bushe,Lovisa Berggren,Marta Casillas,Walter Deberdt	9
14	Individual residual symptoms and functional impairment in patients with depression 2014 ·Psychiatry Research ·Irene Romera,Víctor Pérez,Deborah Quail,Lovisa Berggren,Alan Lenox‐Smith,Inmaculada Gilaberte	19
15	Impact of Pretreatment With Antidepressants on the Efficacy of Duloxetine in Terms of Mood Symptoms and Functioning 2014 ·The Primary Care Companion For CNS Disorders ·(unknown),Alexander Schacht,Michael Happich,(unknown),Lovisa Berggren,Daniel Walker,Héctor Dueñas	2
16	Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practice 2014 ·Journal of Diabetes and its Complications ·Dan Ziegler,Edith Schneider,Frank Boess,Lovisa Berggren,Frank Birklein	18
17	Does Early Improvement in Anxiety Symptoms in Patients with Major Depressive Disorder Affect Remission Rates? A Post-Hoc Analysis of Pooled Duloxetine Clinic Trials 2014 ·(unknown),(unknown),Alexander Schacht,Lovisa Berggren,Daniel Walker,Héctor Dueñas	7
18	Randomized, Double-Blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Elderly Patients with Major Depressive Disorder 2013 ·American Journal of Geriatric Psychiatry ·Heikki Katila,(unknown),(unknown),Lovisa Berggren,Hans Eriksson,Willie Earley,Catherine Datto	41
19	Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses 2013 ·Neuropsychiatric Disease and Treatment ·Antonio Ciudad,Ernie Anand,Lovisa Berggren,Marta Casillas,Alexander Schacht,(unknown)	1
20	Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: A randomized, double-blind, crossover study in healthy adult subjects 2009 ·Clinical Therapeutics ·Catherine Datto,Lovisa Berggren,Jitendra Patel,Hans Eriksson	47

About Lovisa Berggren

Lovisa Berggren is a scholar working on Psychiatry and Mental health, Dermatology and Pharmacology, having authored 27 papers that have together received 392 indexed citations. Recurring topics across this work include Treatment of Major Depression (8 papers), Attention Deficit Hyperactivity Disorder (7 papers) and Psoriasis: Treatment and Pathogenesis (6 papers). The work is most often cited by research in Psychiatry and Mental health (178 citations), Biological Psychiatry (29 citations) and Dermatology (81 citations). Lovisa Berggren has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Catherine Datto, Hans Eriksson, O Hansson, Martín Dossenbach, Jitendra Patel, Yves Dutronc, Chris Bushe, L. Puig, Heikki Katila and Willie Earley. Their work appears in journals such as The Lancet, Journal of Investigative Dermatology and Psychiatry Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact